- ABBV +0.98%
Are Options Traders Betting on a Big Move in AbbVie (ABBV) Stock?
Yahoo Finance · 1 day ago
Search results
May 7, 2024 · AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives.
- 156.31Add to watchlist+1.52 (+0.98%)At close:4:00 PM EDTThu. May 30, 2024156.30 -0.01 (-0.01%)After hrs:7:07 PM EDTThu. May 30, 2024Nasdaq Real Time Price (USD) · Market closed
- Open154.65High156.43Low153.58
- Mkt Cap276.02BP/E (TTM)46.52Div & Yield6.20 & 4.01%
- Prev. Close154.7952 Wk. Low130.9652 Wk. High182.89
What analysts are sayingTop storiesRelated stocks
May 7, 2024 · employees turning possibilities into reality for people and patients. Our products are approved in individual countries for specific uses and the information provided is governed by local regulations. Product availability, name and indicated use may vary by country. Please contact your local AbbVie office to learn more about products available ...
Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing.
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74.
200,000+. patients and healthcare providers reached through our independent healthcare grants in 2022. From drug discovery and development to ensuring our medicines are accessible and affordable, patient needs are what guide our work.
Nov 30, 2023 · NORTH CHICAGO, Ill., and WALTHAM, Mass., Nov. 30, 2023 / PRNewswire / -- AbbVie Inc. (NYSE: ABBV) and ImmunoGen, Inc. (NASDAQ: IMGN) today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE ® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC ...
About AbbVie. We’re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people’s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company.
Mar 25, 2024 · NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 / PRNewswire / -- AbbVie Inc. (NYSE: ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ: LABP) ("Landos") today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients ...
May 7, 2024 · Our Patient Assistance Programs are intended for people that live in the United States, have limited or no health insurance coverage and demonstrate qualifying financial need. In 2022, we assisted nearly 200,000 people. Applying to myAbbVie Assist is simple.
May 7, 2024 · ALPN-101 is a potent inhibitor of both CD28 and ICOS pathways with demonstrated efficacy in multiple preclinical disease models, superior to blockade of either pathway alone. AbbVie and Alpine have entered into an exclusive worldwide option and license agreement for ALPN-101.
